Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Durham, North Carolina 27705


The broad objective of this proposal is to identify functional neuroanatomical correlates of impairments in decision making and response inhibition during smoking abstinence. We will measure changes in performance and regional blood oxygenation levels using fMRI while smokers and non-smokers complete tasks designed to assess decision making and response inhibition. Our primary hypothesis is that smoking abstinence will result in impaired decision making and response inhibition accompanied by decreases in blood-oxygenation-level-dependent (BOLD) fMRI signal in brain regions associated with these cognitive processes including frontal cortex and the ventral striatum. Abstinence may also result in performance-related increases in activation in brain regions associated with effortful processing including the anterior cingulate cortex in effort to compensate for deficits in other regions. We also hypothesize that smokers with a history of diagnosis of ADHD will exhibit greater decreases in brain activity following smoking abstinence. Finally, we hypothesize that smokers during in the satiated state will exhibit brain activity more similar to that of non-smokers.


Inclusion Criteria: - Smoker subjects must have smoked an average of 10 cigarettes per day for two continuous years of a brand that delivers (by Federal Trade Commission rated yields) at least 0.5 mg nicotine, have an expired air carbon monoxide reading of at least 10 ppm. Non-smoker subjects must have smoked less than 50 cigarettes in their lifetime, have not smoked in the last six months, and have an expired air carbon monoxide reading of less than or equal to 5 ppm. Subjects must be in general good health. Participants with controlled medical conditions (e.g., hypertension) will be considered if treatment is not thought to interfere with fMRI measures or potentially ameliorate smoking withdrawal symptoms. Exclusion Criteria: - Individuals with a major medical condition that would make participation unsafe (e.g., have pacemaker or other metallic implant), uncomfortable (e.g., chronic pain), confound results (e.g., psychiatric condition other than ADHD (non-medicated)) suffering from claustrophobia; abnormally afraid of closed-in places will be excluded from participation. Current alcohol or drug abuse, smokeless tobacco use, or use of nicotine replacement therapy or other smoking cessation treatment will also be a basis for exclusion.



Primary Contact:

Principal Investigator
Francis J McClernon, Ph.D
Duke University

Avery M Lutz, BA
Phone: 919-684-9593
Email: lutz0011@mc.duke.edu

Backup Contact:

Email: mccle011@mc.duke.edu
Francis J McClernon, Ph.D.
Phone: 919-668-3987

Location Contact:

Durham, North Carolina 27705
United States

There is no listed contact information for this specific location.

Site Status: Recruiting

Data Source: ClinicalTrials.gov

Date Processed: February 04, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.